PLSMHealthcare · Medical DevicesTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 9 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Pulsenmore Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Volatility (1): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PLSM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PLSM appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 88% of US stocks
Cheaper than 58% of US stocks
Higher than 86% of US stocks
Higher than 18% of US stocks
Higher than 8% of US stocks
Higher than 23% of US stocks
Higher than 29% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pulsenmore Ltd. has a market value of $10.9M and an enterprise value of −$9.2M.
Trailing P/E: −0.7×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Pulsenmore Ltd. employs 71 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pulsenmore Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Pulsenmore appointed David Woods as chief commercial officer and expanded its U.S. commercial team as it scales its presence in the U.S. healthcare market.
Why it matters — The leadership appointment and team expansion relate to Pulsenmore’s efforts to grow its U.S. commercial operations.
Pulsenmore has secured MHRA registration, allowing its Pulsenmore FC home ultrasound platform to be marketed across the United Kingdom and Northern Ireland. This extends the company's fertility platform into the UK market, where more than 100,000 IVF and fertility treatment cycles were performed in 2024.
Why it matters — A UK market entry would give Pulsenmore access to a large fertility-treatment market for its home ultrasound platform, broadening its commercial reach beyond existing regions.
Pulsenmore Ltd. announced that its home ultrasound system for follicular monitoring (the Pulsenmore FC system), designed for women undergoing IVF and fertility preservation treatments, has completed CE European registration. This marks the company's second product authorized in Europe and its first expansion beyond prenatal care into the broader women's health market.
Why it matters — For Pulsenmore watchers, this registration signals a strategic expansion into fertility care and the broader women's health market, broadening the company's product portfolio and European footprint beyond its prenatal care offering.
Pulsenmore Ltd. announced its financial results and business highlights for the six-month period ended June 30, 2026. The company presented key operational, commercial, regulatory, and technological achievements along with financial updates, and management hosted a webcast to discuss the results and provide a business update.
Why it matters — This announcement provides PLSM watchers with the company's latest financial performance and operational progress across its remote maternal-fetal healthcare and home ultrasound business.
Pulsenmore Ltd. announced it will release its financial results and business highlights for the six months ended June 30, 2026 on August 31, 2026 at 8:30 am ET, and will hold a conference call to discuss them. The company, which focuses on remote maternal-fetal healthcare and home ultrasound solutions, issued the announcement from Omer, Israel.
Why it matters — Investors tracking Pulsenmore will be able to review the company's first-half 2026 financial and operational performance when the results and accompanying conference call take place on August 31.
As at 9 Oct 2026, Pulsenmore Ltd. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No analyst covering Pulsenmore Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLSM are extrapolating price history, which says nothing about the business.
Pulsenmore Ltd. is a medical device company that develops portable self-scan ultrasound solutions for remote clinical diagnosis and screening.
The most recent item we track (PRNewsWire, 13 Oct 2026): "Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer". Pulsenmore appointed David Woods as chief commercial officer and expanded its U.S. commercial team as it scales its presence in the U.S. healthcare market.
Pulsenmore Ltd. is a medical device company that develops portable self-scan ultrasound solutions for remote clinical diagnosis and screening. Its current product lineup includes home-use ultrasound systems that connect with a patient’s smartphone, allowing users to capture images for review by healthcare professionals. The company also provides a mobile application that guides patients through the scanning process and supports online consultation, along with a clinician dashboard for remote image review and scan supervision. Pulsenmore Ltd. focuses on applications in telehealth and remote monitoring, with solutions used in maternal health and fertility care. Headquartered in Omer, Israel, Pulsenmore Ltd. serves healthcare providers and patients seeking convenient ultrasound access outside traditional clinical settings.
CEO Dr. Elazar Sonnenschein · 71 employees · Israel · https://www.pulsenmore.com
